FLORTAUCIPIR
Primary Progressive Aphasia
Mayo ClinicSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Primary Progressive Aphasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rotigotine I.R.C.C.S. Fondazione Santa Lucia | Phase 2 | B |
Nabilone Simon Ducharme, MD | Phase 2 | CCC |
Fludeoxyglucose Mayo Clinic | Phase 1 | CC |
Pittsburgh Compound B Unlabelled Mayo Clinic | Phase 1 | CC |
Apsolol University of Missouri-Columbia | Early Phase 1 | C |
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE University of Chicago | Unknown | D |
ER-176 Mayo Clinic | Unknown | D |
Florbetaben University of Chicago | Unknown | D |
Same molecule, other indications
FLORTAUCIPIR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →